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Abstract
Purpose To evaluate the effects of lanreotide Autogel on
patient-reported outcomes and association with biochemi-
cal control, using PRIMARYS data.
Methods PRIMARYS was a 1-year, open-label study of
lanreotide Autogel (Depot in USA) 120 mg every 4 weeks
in 90 treatment-naı¨ve patients with acromegaly. Symptoms
were assessed using Patient-assessed Acromegaly Symp-
tom Questionnaire (PASQ) and health-related quality of
life (HRQoL) using the AcroQoL questionnaire. Correla-
tions between PASQ and AcroQoL scores, and between
PASQ/AcroQoL and growth hormone (GH)/insulin-like
growth factor-1 (IGF-1) levels were also evaluated (post
hoc).
Results Acromegaly symptoms and HRQoL significantly
improved from week 12 to week 48, with modest correla-
tions at week 48 between PASQ total score (R = –0.55,
p\ 0.0001) and AcroQoL global and physical scores
(R = –0.67, p\ 0.0001). Approximately 60 % of patients
achieved a minimal important difference (MID; improve-
ment[50 % of baseline standard deviation) in PASQ total
score and[40 % achieved a MID in AcroQoL global score
(post hoc). Changes in PASQ scores were similar in bio-
chemically controlled (GH levels B2.5 lg/L and normal
IGF-1 levels) and uncontrolled groups, while changes in
global and psychological AcroQoL scores were greater in
the controlled group. There was no correlation between
changes in PASQ or AcroQoL scores and changes in GH or
IGF-1 levels.
Conclusions Primary treatment with lanreotide Autogel
over 1 year was associated with rapid and sustained
improvements in clinical signs and symptoms and HRQoL
in patients with acromegaly. Improvements in HRQoL, but
not symptoms, were greater in those achieving biochemical
control (ClinicalTrials.gov: NCT00690898; EudraCT:
2007–000155–34).
Keywords Acromegaly  Lanreotide Autogel  Quality of
life  Symptoms
Introduction
Acromegaly is a multisystem disease, characterized by
somatic overgrowth, multiple comorbidities (including
diabetes and cardiovascular disorders), premature mortal-
ity, and physical disfigurement [1, 2]. Perhaps not sur-
prisingly, acromegaly is associated with psychological
issues such as mood swings, impaired self-esteem, and
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disruptions in interpersonal relationships [2]. Furthermore,
studies have shown that patients with acromegaly have
impaired health-related quality of life (HRQoL), measured
using both generic and disease-specific (AcroQoL) ques-
tionnaires [3, 4].
Treatment options for acromegaly include surgery, drug
treatment, and radiotherapy. Goals of treatment are ame-
lioration of clinical signs and symptoms, reduction of
morbidity and mortality, and control of GH and IGF-1
hypersecretion and tumor growth [1, 5, 6]. The somato-
statin analogs (SSAs), which include lanreotide Autogel
(Depot in the USA), are largely recognized for their role in
patients whose disease persists despite surgical intervention
[1, 5, 6]. In addition, a number of guidelines on the man-
agement of acromegaly advocate the first-line use of long-
acting SSAs in those who cannot be cured using surgery or
who are poor surgical candidates [1, 5, 6]. SSAs have been
shown to improve acromegaly symptoms and limit GH/
IGF-1 hypersecretion and tumor growth [7–10]. There is
also evidence that SSAs improve HRQoL in acromegaly
[11–13].
PRIMARYS was a robust, 1-year study designed to
evaluate the effect of primary treatment with lanreotide
Autogel 120 mg every 4 weeks in 90 treatment-naı¨ve
patients with acromegaly [7]. The results showed that
clinically significant tumor shrinkage (C20 %) was
achieved in 63 % of patients and there were early and
sustained improvements in growth hormone (GH) and
insulin-like growth factor-1 (IGF-1) levels, acromegaly
symptoms, and HRQoL [7]. Lanreotide Autogel was well
tolerated, with no patients discontinuing treatment due to
gastrointestinal intolerance. The patient population enrol-
led in PRIMARYS was particularly homogeneous: all
patients were treatment naı¨ve and all were treated first-line
with the highest available dose of lanreotide Autogel from
the outset (i.e. there was no dose titration) in order to
achieve rapid efficacy. In view of this, the relatively large
number of patients enrolled, and the long duration of fol-
low-up, we conducted a more in-depth analysis to further
investigate the effects of treatment on patient-reported
outcomes.
Methods
The methods used for this trial (ClinicalTrials.gov:
NCT00690898 and EudraCT: 2007–000155–34) have
previously been described in detail [7].
Patients
The study included treatment-naı¨ve men and women, aged
18–75 years, diagnosed with acromegaly, with mean GH
levels[1 lg/L and IGF-1 levels above the normal age- and
sex-matched range. All patients had a GH-secreting
macroadenoma (diameter C10 mm) without visual field
defects. Patients were excluded if they had: undergone or
were likely to need pituitary surgery or radiotherapy; pre-
viously received treatment with a SSA, dopamine agonist,
or GH receptor antagonist; prolactin co-secretion[100 lg/
L; optic nerve disease or any visual abnormality that may
have worsened during the trial; or a glomerular filtration
rate\30 mL/min/1.73 m2.
Patients could be withdrawn from the study if they had
an insufficient IGF-1 response (\10 % reduction in IGF–1
at Week 24 or an inadequate response in the investigator’s
opinion), if there was suspicion of visual field deteriora-
tion, in the event of a post-baseline prolactin level
[100 lg/L, or if there were any other safety concerns.
Trial design and interventions
This was an international, 48-week, open-label, single-arm
phase 3b trial, conducted in 27 specialist endocrine centers
in nine countries (Belgium, Czech Republic, Finland,
France, Germany, Italy, The Netherlands, Turkey, and the
United Kingdom) between May 20, 2008 and February 13,
2012. Patients received twelve injections of lanreotide
Autogel 120 mg by deep subcutaneous injection every
28 days. Dose titration was not permitted.
All patients gave written informed consent to participate
before the start of the trial, which was conducted in
accordance with the Declaration of Helsinki, Good Clinical
Practice guidelines, and all local regulatory requirements.
Trial documentation was approved by institutional review
boards before the start of the trial.
Assessments and endpoints
Trial visits were conducted at baseline (week 1) and at
weeks 12, 24, and 48. GH and IGF-1 levels were measured
at each trial visit, as described previously [7]. The primary
endpoint (change from baseline in pituitary tumor volume
at week 48) and all secondary endpoints of the trial have
been reported previously; here we present further detailed
analyses on changes in acromegaly symptoms and changes
in HRQoL. Symptoms were assessed at each visit using the
Patient-assessed Acromegaly Symptom Questionnaire
(PASQ), which allows patients to rate five key symptoms
(headache, excessive perspiration, fatigue, soft tissue
swelling, arthralgia) on a 9-point scale (0, no symptoms; 8,
severe incapacitating symptoms) [14]. The total PASQ
score is the sum of the individual symptom scores (maxi-
mum = 40). HRQoL was assessed at each visit using the
AcroQoL questionnaire (except Finland and Turkey, where
validated translations were not available). The AcroQoL
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questionnaire is a reliable, validated tool [3] that assesses
global HRQoL, physical performance, and psychological
wellbeing. The psychological wellbeing dimension is fur-
ther divided into sub-dimensions for ‘appearance’ and
‘personal relationships’. Scores were standardized from 0
to 100, with higher scores in all cases representing better
HRQoL.
Statistical analyses
Summary statistics were based on the intention-to-treat
(ITT) population and calculated for PASQ and AcroQoL
scores at baseline, weeks 12, 24, and 48, and last post-
baseline value available (LVA), and for the change in
scores from baseline at these timepoints. Post hoc analyses
were conducted to determine the percentage of patients
with minimally important differences (MIDs) in PASQ and
AcroQoL scores, defined as a change (improvement)
[50 % of the baseline standard deviation (SD) of each
score [15]. Post hoc analyses were also conducted to
evaluate the following correlations in the overall popula-
tion: total PASQ score versus AcroQoL global, physical
and psychological dimension scores (Pearson correlation);
individual PASQ symptom scores versus AcroQoL global,
physical and psychological dimension scores (Kendall
correlation); total PASQ score versus IGF-1 and GH levels,
and AcroQoL global and subscale scores versus IGF-1 and
GH levels. In all cases, correlations were conducted for
absolute scores at week 48 and for changes in scores from
baseline to week 48. Finally, post hoc analyses were con-
ducted to evaluate baseline characteristics, total PASQ
score, and global and physical AcroQoL dimension scores
in patients with and without biochemical control, defined as
GH levels B2.5 lg/L and normal IGF-1 levels, at LVA.
Results
Patient disposition and baseline characteristics
Ninety patients received treatment and 89 were included in
the ITT population; 26 patients (29 %) withdrew before
week 48 and 64 patients (71 %) completed the trial. The
most common reason for withdrawal was insufficient IGF-
1 response as per protocol at week 12 (n = 18), followed
by consent withdrawn (n = 4), adverse events (n = 3), and
other reasons (n = 1). One patient in the ITT population
did not have data available on biochemical control; for this
reason, there were 88 patients in the overall population in
the current analyses. Of these, all completed the PASQ at
baseline and 83 completed the AcroQoL questionnaire.
Baseline demography and clinical characteristics are
summarized in Table 1 for the overall population and for
those with and without biochemical control, and in Sup-
plementary Table S1 for the 18 patients who withdrew
because of insufficient IGF-1 response. Patients with bio-
chemical control (GH B2.5 lg/L and IGF-1\ULN) at
LVA were significantly older at baseline than those in the
uncontrolled group at LVA, and had significantly lower
baseline IGF-1 levels (Table 1). Patients with biochemical
control tended to be female (70 vs. 45 % in the uncon-
trolled group) and tended to have lower median baseline
tumor volumes (1339 vs. 1786 mm3 in the uncontrolled
group). There were no statistically or clinically significant
differences in baseline characteristics between the group
who withdrew because of insufficient response and the ITT
population excluding these 18 patients (Table 1).
IGF-1, acromegaly symptoms, and HRQoL
in the overall population
As previously reported (7), mean IGF-1 levels were greatly
reduced at week 12 versus baseline, and reductions were
maintained until the end of the trial.
PASQ scores at baseline (n = 88) and during treatment
(week 12, n = 87; week 48, n = 62) are shown in Table 1
and Fig. 1, and the percentage of patients with a MID in
PASQ is shown in Supplementary Figure S1. The most
troublesome symptoms at baseline were fatigue and soft
tissue swelling, whereas headache was least troublesome
(Table 1). The PASQ total score decreased significantly
between baseline and week 12 (mean change, -7.1); this
decrease was maintained at LVA (mean change, -7.6)
(Fig. 1). Early and sustained reductions were also observed
in each of the individual symptom scores. At LVA, greatest
mean change was in excessive perspiration (-1.9) and
smallest mean change was in headache (-0.9). Over half of
patients experienced a MID in their PASQ total score at
week 12 (59 %) and LVA (63 %). For the individual
symptoms, excessive perspiration and soft tissue swelling
showed greatest improvement, with MIDs in 51 %/51 %
(week 12/LVA) and 49 %/62 % of patients, respectively,
while the lowest MID rates were for headache with 26 %/
30 % (Figure S1).
AcroQoL scores at baseline (n = 81–83) and during the
study (week 12, n = 81–82; week 48, n = 57–59) are
shown in Table 1 and Fig. 2, and the percentage of patients
with a MID during treatment is shown in Supplementary
Figure S1. At baseline, the greatest impairment was for the
psychological sub-dimension, appearance and the least
impairment was for the psychological sub-dimension,
personal relationships (Table 1). The improvement in the
global AcroQoL score from baseline was significant at
week 12 (mean change, 8.0) and at LVA (mean change,
7.9) (Fig. 2). During treatment, the greatest improvements
in each of the dimension or sub-dimensions were seen
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between baseline and week 12; these improvements con-
tinued (psychological dimension, appearance sub-dimen-
sion) or remained relatively stable (physical dimension,
personal relationships sub-dimension) through to week 48.
MID rates during treatment for the AcroQoL global score
were 43 % at week 12 and 42 % at LVA, with appearance
showing the greatest improvement (52 %/55 %), and per-
sonal relationships sub-dimension showing the least
improvement (33 %/28 %) (Figure S1).
Correlation analyses in the overall population
For week-48 scores, there was a moderate correlation
between the total PASQ and both global and physical
AcroQoL scores (R = -0.55 and R = -0.67; both
p\ 0.0001), but not psychological AcroQoL dimension
scores (R = -0.27, p = 0.0017; Supplementary Table S3).
The correlations between the total PASQ score andAcroQoL
domain scores were stronger than those between the
Table 1 Baseline demography and disease characteristics in the overall population and according to achievement of biochemical control
Overall population (n = 88)a Patients achieving biochemical
control (n = 30)
Patients not achieving
biochemical control (n = 58)
Age, years 49.5 (46.9, 52.1) 56.1 (52.4, 59.7) 46.1 (42.8, 49.3)
Female, n 47 21 26
% (95 % CI) 53.4 (42.5, 64.1) 70.0 (50.6, 85.3) 44.8 (31.7, 58.5)
BMI, kg/m2 27.7 (26.7, 28.7) 26.4 (24.9, 27.9) 28.4 (27.1, 29.7)
Time since acromegaly diagnosis, days 121.1 (84.6, 157.6) 147.0 (44.8, 249.3) 107.3 (87.1, 127.5)
Maximum tumor diameter, mm
Mean (95 % CI) 18.9 (17.4, 20.4) 17.3 (15.6, 19.1) 19.8 (17.7, 21.9)
Median (interquartile range) 18.1 (13.9, 21.8) 17.2 (13.4, 20.2) 18.2 (14.2, 23.0)
Maximum tumor volume, mm3
Mean (95 % CI) 2731 (2033, 3428) 1822 (1211, 2433) 3201 (2199, 4203)
Median (interquartile range) 1653 (866, 3370) 1339 (811, 2325) 1786 (958, 4404)
GH level, lg/L
Mean (95 % CI) 15.2 (11.2, 19.2) 13.0 (6.6, 19.3) 16.3 (11.1, 21.6)
Median (interquartile range) 8.6 (3.8, 16.8) 6.4 (2.9, 14.9) 9.7 (4.6, 17.3)
IGF-1 level, lg/L
Mean (95 % CI) 796 (735, 857) 665 (563, 767) 863 (792, 935)
Median (interquartile range) 778 (594, 973) 630 (472, 794) 805 (674, 1010)
IGF-1 levels, % of ULN 285 (260.6, 309.3) 249 (211.2, 286.7) 304 (272.6, 334.6)
PASQ scores, mean (95 % CI)
Total 19.4 (17.7, 21.1) 19.8 (16.9, 22.7) 19.2 (17.0, 21.5)
Headache 2.8 (2.2, 3.3) 2.0 (1.2, 2.9) 3.1 (2.5, 3.8)
Excessive perspiration 4.0 (3.4, 4.5) 4.1 (3.2, 5.1) 3.9 (3.2, 4.6)
Fatigue 4.5 (4.0, 5.0) 5.0 (4.1, 5.9) 4.3 (3.7, 4.9)
Soft tissue swelling 4.3 (3.7, 4.8) 4.6 (3.7, 5.5) 4.1 (3.5, 4.7)
Arthralgia 3.9 (3.4, 4.5) 4.1 (3.2, 5.0) 3.8 (3.1, 4.6)
AcroQoL scoresb, mean (95 % CI)
Global 56.0 (52.5, 59.5) 50.9 (45.1, 56.7) 58.8 (54.4, 63.1)
Physical 54.6 (50.4, 58.8) 52.2 (44.6, 59.7) 55.9 (50.7, 61.1)
Psychological 56.9 (53.1, 60.6) 50.2 (44.5, 56.0) 60.5 (55.7, 65.2)
Psychological (appearance) 41.4 (37.0, 45.7) 34.1 (27.8, 40.4) 45.4 (39.7, 51.0)
Psychological (personal relationships) 71.7 (67.6, 75.7) 65.1 (58.0, 72.2) 75.0 (70.1, 79.8)
CI confidence interval, BMI body mass index, IGF-1 insulin-like growth factor-1, GH growth hormone, SD standard deviation, ULN upper limit
of normal
a Excludes one patient in the ITT population with no data available on biochemical control. Data are the mean (95 % CI) unless otherwise
specified; italic cells indicate parameters with non-overlapping CIs for biochemical control and lack of biochemical control (i.e. statistically
significant differences). Biochemical control defined as GH levels B2.5 lg/L and normal IGF-1 levels at last post-baseline value available
b n = 83 for overall population (29 for controlled, 54 for uncontrolled)
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individual PASQ symptom scores and the AcroQoL domain
scores. For changes from baseline to week-48 scores, there
were no correlations between PASQ total/individual symp-
tom scores and AcroQoL domains. Finally, there were no
correlations for week-48 scores or changes from baseline to
week 48 for GH/IGF-1 levels and either PASQ or AcroQoL
scores.
Acromegaly symptoms and HRQoL in patients
according to biochemical response
At baseline, PASQ symptom scores were similar in the two
groups (Table 1). In addition, there were no significant
differences in the change in symptom scores from baseline
to LVA between the biochemically controlled and the
uncontrolled groups (Supplementary Table S4). There was
no significant difference in baseline AcroQoL scores in the
groups with and without subsequent biochemical control
(Table 1). However, the mean [95 % CI] change in the
global AcroQoL score at LVA was significantly higher in
the controlled group (14.4 [9.8–19.0]) than in the uncon-
trolled subjects (4.4 [1.5–7.4]), as were the changes in the
psychological dimension, and the appearance and personal
relationships sub-dimension scores (Fig. 3). Conversely,
there was no significant difference between the controlled
and uncontrolled groups for the physical AcroQoL score at
LVA.
Changes in PASQ total and AcroQoL global scores in
the 18 patients who withdrew because of insufficient IGF-1
response are summarized in Supplementary Figure S2.
Compared with the ITT population excluding these 18
patients, there appeared to be smaller improvements in
PASQ and AcroQoL scores, but between-group differences
were not statistically significant.
Discussion
The results of the current analyses show that primary
medical treatment of acromegaly with lanreotide Autogel
120 mg is associated with early and sustained improve-
ments in patient-reported symptoms and HRQoL.
Improvements were noted across all symptoms evaluated
(headache, excessive perspiration, fatigue, soft tissue
swelling, and arthralgia) and approximately 60 % of
patients had a clinically significant improvement (MID) in
their total symptom score at LVA. Similarly, improve-
ments were noted across all HRQoL dimension and sub-
dimension scores (physical, psychological, appearance, and
personal relationships) and[40 % of patients had a clini-
cally significant improvement in their global HRQoL score
at LVA. Amongst the AcroQoL dimensions and sub-di-
mensions, the greatest proportion of patients had clinically
significant improvements in the appearance sub-dimension.
This sub-dimension also scored worst at baseline, so the
greater effect of treatment may reflect a larger scope for
improvement.
As reported previously [7], mean GH and IGF-1 levels
were significantly reduced at week 12 versus baseline, and
improvements were maintained until the end of the trial.
Improvements in acromegaly symptoms were also greatest
during the first 12 weeks. Interestingly, however, the total
and individual symptom scores during the study did not
differ in those who achieved biochemical control (GH
B2.5 lg/L and normal IGF-1 levels), compared with those
who did not. Furthermore, there were no correlations
between symptom scores and GH or IGF-1 levels. These
results suggest that there may be a dissociation between
hormonal control and symptom improvement, possibly
Fig. 1 Mean (95 % CI) change in PASQ scores during treatment
with Lanreotide Autogel. Each symptom is assessed on a 9-point
scale, total maximum score = 40 (higher scores indicate worse
symptoms); baseline scores are summarized in Table 1. Full data for
this Figure are provided in Supplementary Table S2. CI confidence
interval, PASQ patient-assessed acromegaly symptom questionnaire
Fig. 2 Mean (95 % CI) change in AcroQoL scores during treatment
with Lanreotide Autogel. Scores for each dimension/sub-dimension
are standardized from 0 to 100 (higher scores = better HRQoL);
baseline scores are summarized in Table 1. Full data for this
Figure are provided in Supplementary Table S2. CI confidence
interval, AcroQoL acromegaly quality of life questionnaire
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reflecting patients’ long-term experience of the disease
before diagnosis, the effect of comorbidities, or underlying
differences in baseline characteristics between those with
and without biochemical control (e.g. age and possibly
gender). With regards to HRQoL, there was a modest
correlation between the total PASQ and both global and
physical AcroQoL scores. There were no correlations
between any of these HRQoL scores and GH or IGF-1
levels, but improvements in the global and psychological
AcroQoL scores were significantly greater in those who
achieved biochemical control compared with those who did
not. A number of previous studies have evaluated the
association between HRQoL and biochemical control; the
results are mixed, with some showing better HRQoL in
those with biochemical control, and others showing no
such association [16, 17]. Interestingly, in one study,
IGF-1 control was associated with better scores on the
AcroQoL appearance sub-dimension, but not for the global,
physical or psychological dimensions [18]. In another
study, administration of pegvisomant to patients bio-
chemically controlled with a SSA resulted in an improve-
ment in HRQoL despite no change in IGF-1 levels [14].
Fig. 3 Changes in AcroQoL scores for patients with and without
biochemical control during treatment with Lanreotide Autogel.
AcroQoL acromegaly quality of life questionnaire, CI confidence
interval. Asterisks indicate non-overlapping CIs, i.e. statistically
significant between-group differences. Baseline scores are summa-
rized in Table 1
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The relationship between biochemical control (as deter-
mined by circulating hormones) and HRQoL therefore
remains to be determined, but it should be borne in mind
that HRQoL can be affected by a number of factors asso-
ciated with acromegaly and the treatment modality. These
include cosmetic or orthopedic deformities or comorbidi-
ties, which may already be established in some patients,
particularly in view of the time lag between symptom onset
and diagnosis [16]. It has also been shown that illness
perception affects HRQoL in those with acromegaly [19].
In addition, tissue sensitivity to GH and IGF-1 excess can
vary [14], which may also explain the apparent disconnect
between HRQoL and circulating levels of GH and IGF-1 in
some studies. Finally, it should be borne in mind that the
studies in which HRQoL and biochemical control have
been assessed include heterogeneous populations in terms
of treatments received (surgery, radiotherapy, medical
treatment, or a combination of these) [14, 16–18], which
could also impact on HRQoL. Indeed, one of the strengths
of the current study was the homogeneity of the patient
population, who were all treatment naı¨ve.
Other studies have used the PASQ and AcroQoL to
assess symptoms and HRQoL in those treated for acro-
megaly [9, 12, 20–23]. In the observational ACROSTUDY
of the GH receptor antagonist, pegvisomant, only the
PASQ score for excessive perspiration was significantly
improved following 1 year’s treatment; after 2 years,
numbness and soft tissue swelling were significantly
reduced [20]. HRQoL was assessed using AcroQoL in a
recent randomized study comparing octreotide LAR and
pasireotide LAR in 358 medical treatment-naı¨ve patients;
baseline scores (55.6 and 58.4) were similar to those in the
current study (56.0). After 1 year, scores increased by 4.9
in the octreotide LAR group and 7.0 in the pasireotide
group; the results in the current study (increase of 9.5)
compare well with these [7]. Larger increases in the
AcroQoL global score (?17) were noted with octreotide
LAR in an earlier observational study, but it included only
28 patients treated for 4 years, so the results are more
difficult to compare [12].
One limitation of the current study was its open-label,
uncontrolled design. However, this was felt to be justified
because of the objective nature of the primary endpoint, tumor
volume reduction [7]. Strengths of the study, particularly in
the context of the patient-reported outcomes, include the
relatively large size of the patient population, its homogene-
ity, and the long duration of follow-up. Many of the previ-
ously reported studies evaluating the effect of SSAs on
HRQoL included fewer than 50 patients [12–14, 24–26].
Furthermore, unlikemany of the other studies [11, 12, 14, 26],
patients were treatment naı¨ve, and as such, they represent an
appropriate population for evaluating patient-reported out-
comes and HRQoL in the earlier stages of treatment.
The results of the current study confirmed that medical
treatment with lanreotide provided meaningful improve-
ments not only in hormone levels, but also in clinical
outcomes as evaluated by the PASQ and AcroQoL ques-
tionnaires. The relationship between biochemical and
PASQ improvements was not clear, whereas the associa-
tion between biochemical and AcroQoL improvements was
more apparent. This divergence highlights the importance,
wherever practicable, of using more than one appropriate
questionnaire, in addition to biochemical measures, to fully
evaluate clinical outcomes during medical treatment for
acromegaly. Such an approach will offer different, but
complementary, information on treatment response. In
particular, it is most important to consider using a tool,
such as AcroQoL, that assesses patients’ subjective per-
ceptions of the impact of disease on their daily HRQoL, as
this outcome cannot always be reliably inferred from bio-
chemical markers or objective symptom evaluation.
In conclusion, primary treatment with lanreotide Autogel
120 mg every 4 weeks for 1 year was associated with early
and sustained improvements in signs and symptoms and
HRQoL in patients with acromegaly. Symptom improve-
ment did not appear to depend exclusively on biochemical
control. On the other hand, improvements in HRQoL may
reflect improvements in clinical signs and symptoms in
these patients as well as a decrease of GH/IGF-1 hyper-
secretion. These results highlight the importance of using
appropriate questionnaires to fully evaluate clinical out-
comes during medical treatment for acromegaly.
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